Abstract
One possible explanation for the competitive advantage that malignant cells in patients with acute myelogenous leukemia (AML) appear to have over normal hematopoietic elements is that leukemic progenitors proliferate more rapidly than their normal progenitor cell counterparts. To test this hypothesis, an overnight 3H-thymidine (3H-Tdr) suicide assay was used to analyze the proliferative status of malignant progenitors detected in both colony-forming cell (CFC) and long-term culture initiating cell (LTC-IC) assays from the peripheral blood of nine patients with newly diagnosed AML. Culture of AML cells in serum-free medium with 100 ng/ml Steel factor (SF), 20 ng/ml interleukin 3 (IL-3) and 20 ng/ml granulocyte colony-stimulating factor (G-CSF) for 16–24 h maintained the number of AML-CFC and LTC-IC at near input values (mean % input ± s.d. for CFC and LTC-IC were 78 ± 33 and 126 ± 53, respectively). The addition of 20 μCi/ml high specific activity 3H-Tdr to these cultures reduced the numbers of both progenitor cell types from most of the patient samples substantially: mean % kill ± s.d. for AML-CFC and LTC-IC were 64 ± 27 and 82 ± 16, respectively, indicating that a large proportion of both progenitor populations were actively cycling. FISH analysis of colonies from CFC and LTC-IC assays confirmed that most cytogenetically abnormal CFC and LTC-IC were actively cycling (mean % kill ± s.d.: 68 ± 26 and 85 ± 13, respectively). Interestingly, in six patient samples where a significant number of cytogenetically normal LTC-ICs were detected, the % kill of these cells (74 ± 20) was similar to that of the abnormal progenitors. These data contrast with the predominantly quiescent cell cycle status of CFC and LTC-IC previously observed in steady-state peripheral blood from normal individuals but also provide evidence that a significant proportion of primitive malignant progenitors from AML patients are quiescent and therefore may be resistant to standard chemotherapeutic regimens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McCulloch EA . Stem cells in normal and leukemic hemopoiesis Blood 1983 62: 1–13
Haase D, Feuring-Buske M, Konemann S, Fonatsch C, Troff C, Verbeek W, Pekrun A, Hiddemann W, Wormann B . Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations Blood 1995 86: 2906–2912
Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nature Med 1997 3: 730–736
Sutherland HJ, Blair A, Zapf RW . Characterization of a hierarchy in human acute myeloid leukemia progenitor cells Blood 1996 87: 4754–4761
Ailles LE, Gerhard B, Kawagoe H, Hogge DE . Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice Blood 1999 94: 1761–1772
Buick RN, Till JE, McCulloch EA . Colony assay for proliferative blast cells circulating in myeloblastic leukemia Lancet 1977 1: 862–863
Ailles LE, Gerhard B, Hogge DE . Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines Blood 1997 90: 2555–2564
Minden MD, Till JE, McCulloch EA . Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML) Blood 1978 52: 592–600
Ponchio L, Conneally E, Eaves C . Quantitation of the quiescent fraction of longterm culture-initiating cells (LTC-IC) in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro Blood 1995 86: 3314–3321
Eaves CJ, Eaves AC . Regulation of hemopoietic progenitor cell proliferation Behring Inst Mitt 1988 83: 85–92
Young DC, Wagner K, Griffin JD . Constitutive expression of the granulocyte–macrophage colony-stimulating factor gene in acute myeloblastic leukemia J Clin Invest 1987 79: 100–106
Oster W, Cicco NA, Klein H, Hirano T, Kishimoto T, Lindemann A, Mertelsmann RH, Hermann F . Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia J Clin Invest 1989 84: 451–457
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group Ann Intern Med 1985 103: 620–625
Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ . Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor Blood 1996 88: 3765–3773
Avanzi GC, Lista P, Giovinazzo B, Miniero R, Saglio G, Benetton G, Coda R, Cattoretti G, Pegoraro L . Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features Br J Haematol 1988 69: 359–366
Otsuka T, Thacker JD, Eaves CJ, Hogge DE . Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells J Clin Invest 1991 88: 417–422
Fraser C, Eaves CJ, Kalousek DK . Fluorodeoxyuridine synchronization of hemopoietic colonies Cancer Genet Cytogenet 1987 24: 1–6
Lengauer C, Green ED, Cremer T . Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification Genomics 1992 13: 826–828
Coulombel L, Eaves C, Kalousek D, Gupta C, Eaves A . Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases J Clin Invest 1985 75: 961–969
Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE . Expression of Hox genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells Leukemia 1999 13: 687–698
Ponchio L, Eaves C, Hogge D, Perotti C, Torretta L, Cerani P, Salvaneschi L, Ascari E, Cazzola M . Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF Br J Haematol 1997 99: 394–402
Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R . Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia New Engl J Med 1987 317: 468–473
Fearon ER, Burke PJ, Schiffer CA, Zehnbauer BA, Vogelstein B . Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia New Engl J Med 1986 315: 15–24
Busque L, Gilliland DG . Clonal evolution in acute myeloid leukemia Blood 1993 82: 337–342
Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK . Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia Mol Cell Biol 1997 17: 495–505
Gale RE, Wheadon H, Goldstone AH, Burnett AK, Linch DC . Frequency of clonal remission in acute myeloid leukaemia Lancet 1993 341: 138–142
LoCoco F, Pelicci PG, D'Adamo F, Diverio D, Alimena G, Montefusco E, Arcese W, Avvisati G, De Felice L, Meloni G, Nervi C, Mandelli F, Saglio G . Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements Blood 1993 82: 606–612
Busque L, Zhu J, Dehart D, Griffith B, Willman C, Carroll R, Black PMcL, Gilliland DG . An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X Nucleic Acids Res 1994 22: 697–698
Russell NH, Hunter AE, Bradbury D, Zhu YM, Keith F . Biological features of leukaemic cells associated with autonomo growth and reduced survival in acute myeloblastic leukaemia Leuk Lymphoma 1995 16: 223–229
Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, Lenny N, Hiebert SW . Expression of the AML-1 oncogene shortens the G(1) phase of t cell cycle J Biol Chem 2000 275: 3438–3445
Terpstra W, Ploemacher RE, Prins A, van Lom K, Pouwels K, Wognum AW, Wagemaker G, Lowenberg B, Wielenga JJ . Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture Blood 1996 88: 1944–1950
Ponchio L, Cashman J, Zoumbos N, Eaves CJ, Eaves A . Primitive CML cells show a deregulation of their cycling status both in vivo and in longterm cultures which is not normalized in the presence of interferon-α Blood 1995 86: 493a
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guan, Y., Hogge, D. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 14, 2135–2141 (2000). https://doi.org/10.1038/sj.leu.2401975
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401975
Keywords
This article is cited by
-
Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes
Nature Communications (2018)
-
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
BMC Medical Genomics (2017)
-
Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment
Leukemia (2008)
-
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
Nature Medicine (2006)
-
Concepts of human leukemic development
Oncogene (2004)